(A) ATG5 expression in ESCC tissue was analyzed by IHC and scored as 0, 1+, 2+, and 3+. (B) Expression level of ATG5 in adjacent non-cancerous (normal) and early-stage ESCC tissues by IHC. (C-D) Kaplan–Meier estimates of OS (C) and PFS (D) by the expression levels of ATG5 (low and high) of adjacent normal tissue from early-stage ESCC patients. MST: median survival time. Low, expression score 0 or 1+; High, expression score 2+ or 3+.

Western Blot: ATG5 Antibody - BSA Free [TA301481] - Western blot analysis of total protein from Human HeLa and A431 and Mouse MEF cells. Lysates were separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-ATG5 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.

Knockdown Validated: ATG5 Antibody - BSA Free [TA301481] - Knockdown of autophagy-related gene 5 (ATG5) inhibits trehalose-induced autophagy in normal human primary airway epithelial cells. Normal human tracheobronchial epithelial cells were transfected with Naito1 chimera RNAi (control siRNA) or ATG5 chimera siRNA (ATG5 siRNA). Twenty-four hours after siRNA transfection, cells were treated with medium or trehalose (TRE, 100 mM) for 48 h. ATG5 protein as examined by Western blot analysis with GAPDH protein used as loading control. The representative Western blot picture was shown from 2 independent experiments with each being performed in triplicate wells.